Search results
Is Eli Lilly Stock A Buy Or A Sell As FDA Plans Meeting To Discuss Alzheimer's Drug?
Investor's Business Daily· 17 hours agoIn the first quarter, sales of weight-loss drug Zepbound skyrocketed and topped Wall Street's...
Lilly's next-gen obesity drug brings Innovent a phase 3 win in diabetes
FierceBiotech· 22 hours agoInnovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli...
GLP-1s: 8 things hospital leaders should know
Becker’s Hospital Review· 2 days agoA blockbuster drug class that includes Ozempic, Wegovy and Trulicity is pioneering avenues in the healthcare industry and redefining obesity care as the weight loss therapy ...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks via Yahoo Finance· 7 days agoStrong demand for Mounjaro, Zepbound, Verzenio and Jardiance pulled the top line in the quarter....
Some Patients Suffered Psychiatric Issues After Ozempic Initiation
MedPage Today· 5 days agoSome patients who newly started a GLP-1 receptor agonist quickly developed psychiatric symptoms, a...
Eli Lilly and Company (NYSE:LLY) Trading 2.6% Higher After Strong Earnings
ETF DAILY NEWS· 3 days agoEli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.6% during trading on Monday following a stronger than expected earnings report. Eli Lilly and Company had a return on equity ...
About 79% of the S&P 500 names beat on EPS this week - Earnings
Seeking Alpha· 5 days agoA recap of the first quarter earnings week on Wall Street, highlighting the performances of big...
Considering GLP-1s: A Guide to Deciding If It's Right for You
Healthline· 4 days agoModern medicine is continually advancing treatment options for many chronic health conditions. For...
Eli Lilly and Company (NYSE:LLY) Announces Earnings Results, Beats Expectations By $0.05 EPS
ETF DAILY NEWS· 7 days agoEli Lilly and Company (NYSE:LLY – Get Free Report) released its earnings results on Tuesday. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05, ...
PlanetDrugsDirect.com Expands Access to Diabetic and Weight-Loss Medications Through Cost
Digital Journal· 3 days agoThe company is also exploring expanding its offerings to include newer GLP-1 medications such as Wegovy, Trulicity, and Victoza, anticipating similar cost reductions for these ...